Subtype
Osteosarcoma
CI-CAN-00001321Explore in graph →
Loading cancer entity…
Subtype
CI-CAN-00001321Explore in graph →
Variants & evidence
11 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| ATRX Underexpression1 | |||||||
| AZ20 + VE-821Substitutes | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID5832Loss of the chromatin-remodeling protein ATRX associates with ALT in cancers. Inhibition of the protein kinase ATR, a critical regulator of recombination recruited by RPA, disrupts ALT and triggers ch… (full text at CIViC) PMID 25593184 · Flynn et al., 2015 · Open in CIViC | civic |
| CXCL10 EXPRESSION1 | |||||||
| (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID8026In this retrospective circulating biomarker study, in two cohorts of osteosarcoma patients, the cytokine in blood samples was measured by Luminex assay. The cutoff values for cytokine was determined b… (full text at CIViC) PMID 27529817 · Flores et al., 2017 · Open in CIViC | civic |
| ERCC2 K751Q1 | |||||||
| Cisplatin | Predictive | B | Supports Resistance | 4 | accepted | EID676The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median ag… (full text at CIViC) PMID 19434073 · Caronia et al., 2009 · Open in CIViC | civic |
| NTRK3 e1::e41 | |||||||
| (oncogenic) | Oncogenic | C | Does Not Support Oncogenicity | 3 | accepted | EID11699Using next-generation DNA and RNA sequencing, three cases harboring NTRK fusions were identified in a cohort of 113 osteosarcomas, including primary tumors and metastases. All three cases exhibited hi… (full text at CIViC) PMID 32022484 · Ameline et al., 2020 · Open in CIViC | civic |
| RB1 Loss-of-function1 | |||||||
| Niraparib + Olaparib + TalazoparibSubstitutes | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID12032The study investigated the sensitivity of RB1-mutant osteosarcoma cell lines to PARPi. It found that cell viability, measured by AUC values after 5 days, was significantly lower in RB1-defective cell … (full text at CIViC) PMID 34862364 · Zoumpoulidou et al., 2021 · Open in CIViC | civic |
| TP53 R273H1 | |||||||
| Doxorubicin + MethotrexateSubstitutes | Predictive | D | Supports Resistance | 3 | accepted | EID7430Several preclinical studies were testing drug resistance mechanisms of TP53-R273H variant. Saos-2 cells were transfected with TP53-R273H mutation and these cells were used in the study. Using a wester… (full text at CIViC) PMID 17363498 · Wong et al., 2007 · Open in CIViC | civic |
| TP53 Rearrangement2 | |||||||
| (diagnostic) | Diagnostic | B | Supports Positive | 5 | submitted | EID9247Intron 1 rearrangements of TP53 were identified in 46 of 288 osteosarcoma cases (16%). No fusions were detected in 1090 other tumors screened. Fusions were associated with loss of TP53 expression. PMID 25762628 · Ribi et al., 2015 · Open in CIViC | civic |
| 〃 | Diagnostic | B | Supports Positive | 4 | submitted | EID9248TP53 fusions were identified in 10 of 25 osteosarcoma cases. The resulting inactivation of p53 was demonstrated by a deficiency of the radiation-induced DNA damage response. PMID 26672768 · Lorenz et al., 2016 · Open in CIViC | civic |
| NTRK2 e6::e71 | |||||||
| (oncogenic) | Oncogenic | C | Does Not Support Oncogenicity | 3 | accepted | EID11697Using next-generation DNA and RNA sequencing, three cases harboring NTRK fusions were identified in a cohort of 113 osteosarcomas (including both primary tumors and metastases). Each of the three case… (full text at CIViC) PMID 32022484 · Ameline et al., 2020 · Open in CIViC | civic |
| NTRK3 e4::e11 | |||||||
| (oncogenic) | Oncogenic | C | Does Not Support Oncogenicity | 3 | accepted | EID11698Using next-generation DNA and RNA sequencing, three cases harboring NTRK fusions were identified in a cohort of 113 osteosarcomas (including primary tumors and metastases). Each of the three cases had… (full text at CIViC) PMID 32022484 · Ameline et al., 2020 · Open in CIViC | civic |
| ZNF217 Overexpression1 | |||||||
| Triciribine | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID12210In an orthotopic mouse model of osteosarcoma (OSA), triciribine (TCN) treatment significantly reduces tumour growth and weight in both SJSA-1 and HOS cell line injections, with 5.4- and 3.0-fold reduc… (full text at CIViC) PMID 32999043 · Smeester et al., 2020 · Open in CIViC | civic |
Data updated 22 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.